Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC). Ren K, Wang S, Ye T, Zhu Z, et al. BMC Cancer 2024;24:1237.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ren K, Wang S, Ye T, Zhu Z, et al. Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC). BMC Cancer 2024;24:1237.
PMID: 39375657